Search

News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice

Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.

Source: Kidney Carcinoma 26. 6. 2021

News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?

The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.

Source: Anticoagulant Treatment 14. 4. 2021

News Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC

Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis presented below compared the efficacy and safety of gefitinib in combination with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC.

Source: Oncological Treatment 15. 10. 2021

News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic

In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).

Source: Treatment of Gastrointestinal Carcinomas 15. 10. 2021

News Evaluation of Treatment Response in CLL

The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed, stabilized, or if the patient has achieved partial or complete remission after therapy. An even deeper insight into what has happened at the cellular level in the human body is provided by the evaluation of minimal residual disease (MRD). Why is it meaningful to search for the remaining leukemic cells? How to identify them, in what material, and when? And is the information about MRD truly useful for all types and lines of treatment? The answers to these questions, along with other current data and information on the topic, are brought by the following presentation.

Source: Chronic Lymphocytic Leukemia 9. 9. 2021

News Final Analysis of the STASEY Study: How Did Emicizumab Fare in the Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?

The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a variety of interesting topics. Among the poster presentations, data from the multicenter, single-arm, open-label phase III STASEY clinical trial, which evaluated the safety and tolerability of emicizumab prophylaxis in patients with hemophilia A and an FVIII inhibitor, were included. The results were presented on behalf of an international team of authors by Víctor Jiménez-Yuste from the University Hospital La Paz in Madrid.

Source: Rare Diseases in Hematology 21. 10. 2021

News Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin

Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases. Empagliflozin is among the modern oral antidiabetic medications, and in 2015 it became a pioneer among diabetes treatments shown to reduce the incidence of major CV events. It has also been proven to reduce the risk of hospitalization for heart failure.

Source: Heart Failure 18. 11. 2021

News Comparable Long-term Safety of Tofacitinib and Biologics in RA Treatment –⁠ Data from a US Registry

An analysis of the long-term safety profile of tofacitinib in real clinical practice was published in the journal of the American College of Rheumatology (ACR). Patients with rheumatoid arthritis (RA) who started treatment with tofacitinib showed a similar frequency of predefined adverse events of special interest compared to a cohort treated with biological disease-modifying antirheumatic drugs (bDMARDs).

Source: Arthritis 18. 11. 2021

News HAE Junior Helps Improve the Quality of Life for Pediatric Patients

Living with hereditary angioedema (HAE) brings chronic health issues, long-term psychological stress, and a lifelong threat of death. Initial symptoms of HAE appear during childhood or adolescence. Many patients, however, remain misdiagnosed for a long time. The patient organization HAE Junior strives for a better quality of life for patients with this condition by improving awareness and access to modern therapy.

Source: Hereditary Angioedema 24. 11. 2021

News Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA

Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A is not always simple. An interesting perspective and recommendations are provided by a model analysis assessing the cost and effectiveness of individual available preparations.

Source: Hemophilia 1. 11. 2021

News Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Adolescents

In the pediatric population, atopic dermatitis (AD) has a relatively high prevalence, but therapeutic options are often limited. The following article offers a summary of the results from a clinical study published last year focusing on the efficacy and safety of dupilumab in adolescent patients with moderate to severe AD that is not adequately controlled by topical therapy.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 11. 2021

News Association between Cardiovascular Risk Factors and Cognitive Disorders in Patients with Schizophrenia

Schizophrenia is a disease characterized by a certain degree of cognitive impairment, but also an increased risk of cardiovascular diseases, which are often the cause of deteriorating cognitive functions in the general population. The aim of a large meta-analysis was to elucidate the association between cardiovascular risk factors and cognitive disorders in patients with schizophrenia and schizoaffective disorder, based on the results of a previous smaller study that demonstrated an association between metabolic syndrome, diabetes, and cognitive disorders.

Source: Modern Treatment of Schizophrenia 27. 10. 2021

News Does Teriflunomide Bloom at Every Age?

What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in real-world clinical practice? How do the outcomes differ for patients treated with teriflunomide considering their age and previous therapy? The authors of a study published this year in the journal Therapeutic Advances in Neurological Disorders focused on the efficacy and safety of teriflunomide in real-world clinical practice with regard to age and prior treatment.

Source: Multiple Sclerosis 18. 10. 2021

News Prevention of Symptomatic Skeletal Events in Postmenopausal Women with Advanced ER-Positive Breast Cancer

Advanced breast cancer with the presence of estrogen receptors is one of the most common cancers worldwide. Hormonal treatment for this malignancy is highly effective, but it is accompanied by risks such as symptomatic skeletal events (SSE). However, this undesired anti-estrogen effect can be prevented by administering appropriate antiresorptive drugs. A retrospective study by Hong Kong researchers focused on the effectiveness of these drugs in clinical practice.

Source: Prevention of Bone Events 16. 11. 2022

Články časopisu 3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma)

Author of the article: Julia Liebers, Patrick Wurzel, Kerstin Bianca Reisinger, Martin-Leo Hansmann Source: PLOS One | 10/2019 1. 10. 2019